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independently associated with OA severity (KL score), WOMAC pain and
elevations of biomarkers – PGE2 and COMP fragments. Our data suggest
that increased iron (ferritin levels) may promote cartilage damage in
patients with knee OA and merits further investigation as a biomarker
of disease severity and progression.
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SAFETY AND EFFICACY OF NSAIDs IN ELDERLY ARTHRITIS PATIENTS:
A SUBGROUP ANALYSIS
H. Kellner1, M. Essex2, C. Li3. 1Div. of Rheumatology, Ctr. for Inﬂammatory
Joint Diseases, Munich, Germany; 2Pﬁzer Inc, New York, NY, USA; 3Pﬁzer
Inc., New York, NY, USA
Purpose: As increasing age is a well-known risk factor for gastrointestinal
(GI) adverse events and may contribute to reduced compliance and
discontinuation of therapy, we set out to compare the safety and efﬁcacy
of celecoxib vs diclofenac slow release (SR) plus omeprazole in elderly
patients with arthritis.
Methods: Patients aged ≥65 years, with osteoarthritis and/or rheumatoid
arthritis at increased GI risk who participated in the CONDOR trial
(Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis
and Rheumatoid Arthritis) were included in this subgroup analysis. The
CONDOR trial was a 6-month, prospective, double-blind, randomized
clinical trial of celecoxib vs omeprazole and diclofenac SR. Eligible
patients were expected to need nonsteroidal anti-inﬂammatory drugs
(NSAID) therapy for at least 6 months; aspirin or antiplatelet users
were excluded. Patients were Helicobacter pylori negative. The primary
end point was a composite of clinically signiﬁcant upper and lower GI
events adjudicated by an independent blinded expert committee and
analyzed using a life-table method. Patients were randomized to either
celecoxib 200mg bid or diclofenac SR 75mg bid plus omeprazole 20mg
qd. Follow up visits were at 1, 2, 4, and 6 months from baseline. Efﬁcacy
was determined by Patients’ Global Assessment of Arthritis at each visit.
Results: 2446 patients aged ≥65 years comprised the intent-to-treat
population (n =1219 celecoxib; n = 1227 diclofenac SR). Mean (SD) age
was 70.4 (4.5) years for both arms; 83.0% of celecoxib and 80.8% of
diclofenac SR patients were female. The majority of patients were
white (54.1% celecoxib; 52.2% diclofenac SR). The difference between
the 2 incidence proportions of adjudicated primary GI end points in
patients aged ≥65 years, controlling for region, history of gastroduodenal
ulceration, and time-block was statistically signiﬁcant (odds ratio, 6.27;
P < 0.0001 favoring celecoxib). 76.9% of celecoxib and 72.0% of diclofenac
SR patients completed the study. Among those treated, 9.5% and 14.3%
of patients, respectively, discontinued treatment for reasons related to
study drug, and there were 2 deaths in the celecoxib arm and 1 in the
diclofenac SR arm. Patients’ Global Assessment of Arthritis was 3.2±0.7
at baseline and 2.4±0.8 at Month 6 for both celecoxib and diclofenac SR,
respectively. Similar percentages of patients rated efﬁcacy at good/very
good at baseline and Month 6 for celecoxib (10.5%, 55.9%) and diclofenac
SR (10.6%, 56.4%). Least squares mean (SE) at Month 6 (last observation
carried forward) was 2.539 (0.034) and 2.521 (0.033) for celecoxib and
diclofenac SR (P=NS), respectively.
Conclusions: The results of the CONDOR trial, in which celecoxib was
superior to diclofenac SR plus omeprazole in reducing the risk of clinical
outcomes across the entire GI tract, were conﬁrmed in a subgroup
analysis of patients ≥65 years. The safety and efﬁcacy of both treatments
was comparable in this population. These data may help physicians make
more informed decisions in treating elderly patients with arthritis.
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SAFETY AND EFFICACY OF RETREATMENT WITH A BIOENGINEERED
HYALURONATE FOR PAINFUL OSTEOARTHRITIS OF THE KNEE: RESULTS
OF THE OPEN-LABEL EXTENSION STUDY OF THE FLEXX TRIAL
R.D. Altman1, J.E. Rosen2, D.A. Bloch3, H.T. Hatoum4. 1UCLA, Agua Dulce,
CA, USA; 2New York Hosp., Queens, NY, USA; 3Stanford Univ., Stanford, CA,
USA; 4Univ. of Illinois, Chicago, IL, USA
Purpose: Intra-articular (IA) injection of hyaluronate (HA) has been
shown to be safe and effective for relieving pain in patients with
osteoarthritis (OA) of the knee and is recommended for patients who
cannot be effectively managed with non-pharmacologic interventions or
simple analgesics. Although many studies support the safety and efﬁcacy
of single course IA-HA injections, fewer trials have evaluated the risks and
beneﬁts of repeated series of injections. This 26 week Extension Study of
the FLEXX Trial was conducted to evaluate the safety of repeated intra-
articular (IA) injections of Euﬂexxa® (1% sodium hyaluronate; IA-BioHA)
for painful knee osteoarthritis (OA).
Methods: Participants who completed the randomized, double-blind,
26-week FLEXX Trial and who elected to participate in the Extension
Study received asecond series of3 weekly IA-BioHA injections and were
followed for an additional 26 weeks. Adverse events (AEs) were recorded
and the effect of treatment on knee pain was measured following a 50-
foot walk test using a 100mm visual analog scale (VAS). The 3 subscales
of WOMAC, OARSI responder rate, Patient Global Assessment, SF-36, and
intake of rescue medication was also evaluated.
Results: TheFLEXX Trial included 588 subjects with painful knee OA
who received 3 weekly IA injections of either BioHA or buffered saline
(IA-SA). Results from the FLEXX Trial showed that IA-BioHA decreased
mean pain 100mm visual analog scale (VAS) scores immediately after
a 50-foot walk test by −25.7mm versus −18.5mm for the IA-SA group.
Both treatments were well tolerated with about 1% of subjects in each
group reporting injection site reactions.
The Extension Study included 433 subjects, 219 who received IA-BioHA
and 214 who received IA-SA during the FLEXX Trial. Safety results from
the Extension Study indicate that 43.4% (188/433) of subjects had AEs,
of which 4.8% (21/433) were deemed treatment-related AEs. Two AEs
in the Extension study led to discontinuation, and no joint effusion was
reported. Patients who continued with IA-BioHA in the Extension Study
maintained their improvement from baseline, with an average further
reduction in pain VAS score of −3.5mm. Patients initially treated with
IA-SA in the FLEXX Trial also had a reduction in pain VAS score of
−9.0mm. The OMERACT-OARSI responder rate for all subjects was 75.3%
at the completion of the Extension Study. WOMAC Pain, Stiffness, and
Disability scores decreased by 47.2%, 42.5%, and 44.1%, respectively. The
Patient’s Global Assessment improved an additional −8.1mm and there
were 15.2% and 15.7% improvements for SF-36 physical functioning and
bodily pain scores, respectively, from the beginning of the FLEXX Trial to
the end of the Extension Study. Acetaminophen use was reduced from
14.6 to 9.5 tablets per week, representing an overall 34.9% reduction
from the beginning of the FLEXX Trial.
Conclusions: Repeated injections of IA-BioHA were effective, safe, and
well-tolerated, and were not associated with an increase in AEs such
as synovial effusions. Additional symptom improvements during the
Extension Study were noted for subjects who received either IA-BioHA
or IA-SA during the FLEXX Trial.
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A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A
NOVEL, PROPRIETARY, NANO-FORMULATED ORAL DICLOFENAC
S. Daniels1, G. Manvelian2, A. Gibofsky3. 1Premier Res. Group, Austin, TX,
USA; 2Independent Clinical Res. Consultant, Poway, CA, USA; 3Hosp. for
Special Surgery, New York, NY, USA
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
class of medication taken for acute arthritic pain. However, associated
adverse events (AE) have prompted the development of new
formulations that minimize AEs and maintain efﬁcacy. The purpose
of this clinical study was to evaluate the analgesic efﬁcacy and
safety of an investigational, proprietary, nano-formulated, oral diclofenac
(diclofenac-N) compared with placebo in subjects with acute dental
pain.
Methods: This was a phase-2, multisite, randomized, double-blind,
single-dose, parallel-group, active- and placebo-controlled study. In total,
200 subjects who were 18–50 years of age, had extraction of ≥2 third
molars (at least one of which had to be a fully or partially impacted
mandibular third molar), and experienced moderate to severe pain
intensity within 6 hours after surgery were enrolled. Subjects received
either diclofenac-N 35mg or 18mg, celecoxib 400mg, or placebo. The
primary efﬁcacy variable was the sum of total pain relief (TOTPAR) over
0–12 hours (TOTPAR-12) after Time 0. Higher scores indicated better
pain relief. TOTPAR-8 and TOTPAR-4 were also evaluated.
Results: Diclofenac-N was signiﬁcantly (p < 0.001) better than placebo
for TOTPAR-12. Mean±SD TOTPAR-12 values for diclofenac-N 35mg,
diclofenac-N 18mg, celecoxib 400mg, and placebo were 16.81±12.76,
17.76±13.76, 14.61±15.05, and 5.65±11.53, respectively. TOTPAR-4 and
TOTPAR-8 values for diclofenac-N 35mg and diclofenac-N 18mg
demonstrated comparable results when compared to placebo. The
difference in time-to-onset of analgesia between each treatment
Poster Presentations / Osteoarthritis and Cartilage 19S1 (2011) S53–S236 S145
and placebo was also signiﬁcant (p < 0.001) with the shortest times
observed with diclofenac-N. Treatment-emergent AEs were similar across
treatment groups with similar rates in subjects treated with placebo
(52.9%), diclofenac-N 35mg (60.8%) and diclofenac-N 18mg (55.1%).
Conclusions: An investigational, proprietary, nano-formulated, lower
dose, oral diclofenac demonstrated good efﬁcacy, onset of action, and
tolerability. As suggested by this phase-2 clinical trial, use of this lower
dose formulation could maintain efﬁcacy, shorten onset of action, and
possibly result in an improved tolerability proﬁle for patients with acute
arthritic pain.
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THE APPLICATION OF PLATELET-RICH PLASMA IN EARLY
OSTEOARTHRITIS OF KNEE
S-J. Jang. Kosin Univ. Gospel Hosp., Busan, Korea, Republic of
Purpose: Platelet-rich plasma (PRP) is a natural concentrate of
autologous blood growth factors experimented in different ﬁelds of
medicine in order to test its potential to enhance tissue regeneration,
and so emerged as a treatment option for tendinopathies and chronic
wounds. In addition to release of growth factors, PRP also promotes
concentrated anti-inﬂammatory signals including interleukin-1a, which
has been a focus of emerging treatments for osteoarthritis. The
primary objective is to compare a single, intra-articular injection of
platelet-rich plasma (PRP) with hyruan injection in patients with early
osteoarthritis of knee and to assess the clinical efﬁcacy and safety of
intra-articular platelet-rich plasma (PRP) injection in patients with low
degree osteoarthritis (OA) of the knee.
Methods: Between June 2008 and October 2010, we reviewed the
results of 86 consecutive primary osteoarthritic patients underwent
intra-articular injection of PRP.In a group of early osteoarthritis patients,
inclusion criteria was set to those who were able to be followed up for
at least 6 months and showed as Kellgren-Lawrence grade I on simple
radiograph or MRI, and exclusion criteria was set as severe obesity,
infection, immunosuppressed patients, advanced osteoarthritis(K-L grade
I, II, III), and severe deformity. PRP was injected once, in principle. Also,
to compare the effects of PRP, hyruan injection was performed in 21
cases during the same period in a same target group, and the effect
was compared by perfoming 3 times in an interval of 1 week. Results
were evaluated at 4, 8, 12, 18, 24 weeks post-injection using radiologic
study, visual analogue scale (VAS) and international knee documentation
committee (IKDC) score for functional score.
Results: According to VAS, the mean preoperative scale was 8.2 (range
7–10) and the mean postoperative scale was 3.2 (range 1–4) and 2.9
(range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
Conclusions: According to VAS, the mean preoperative scale was 8.2
(range 7–10) and the mean postoperative scale was 3.2 (range 1–4) and
2.9 (range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
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A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A
NOVEL, PROPRIETARY, NANO-FORMULATED ORAL INDOMETHACIN
G. Manvelian1, S. Daniels2. 1Independent Clinical Res. Consultant, Poway,
CA, USA; 2Premier Res. Group, Austin, TX, USA
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
medication taken for acute pain relief. Indomethacin has a long-
established efﬁcacy and safety proﬁle yet can have a variable and
somewhat slow onset of action. Indomethacin also has the potential
for gastrointestinal adverse events (AEs), suggesting the need for a
new formulation which can safely provide fast onset of acute pain
relief. Our objective was to evaluate the analgesic efﬁcacy and safety
of an investigational, proprietary, nano-formulated, oral indomethacin
compared with placebo in subjects with acute dental pain.
Methods: This was a phase-2, multicenter, randomized, double-blind,
single-dose, parallel-group, placebo-controlled study. In total, 203
subjects were enrolled who: were 18–50 years of age, had extraction
of ≥2 third molars, and experienced moderate to severe pain intensity
within 6 hours after surgery. Subjects received either nano-formulated
indomethacin 20mg, 40mg, or placebo. The primary efﬁcacy variable
was the sum of total pain relief (TOTPAR) over 8 hours (TOTPAR-8).
Higher scores indicated better pain relief.
Results: Nano-formulated indomethacin was signiﬁcantly (p< 0.001)
better than placebo for TOTPAR-8 (mean; 95% CI): 40mg (12.56; 2.64);
20mg (10.79; 2.66); placebo (3.02; 2.64). Nano-formulated indomethacin
was also signiﬁcantly (p < 0.001) better than placebo for TOTPAR-4
(mean; 95% CI): 40mg (6.16; 4.78); 20mg (5.47; 4.61); placebo (1.63;
2.83). The difference in time to onset of analgesia between each
treatment and placebo was also signiﬁcant (p < 0.001). Treatment-
emergent AEs occurred less often in subjects treated with nano-
formulated indomethacin 20mg (38.0%) than those treated with nano-
formulated indomethacin 40mg (51.0%) or placebo (56.9%).
Conclusions: A proprietary, nano-formulated, lower dose, oral
indomethacin demonstrated good efﬁcacy, onset of action, and
tolerability. The ability to utilize a lower dose and maintain efﬁcacy
could result in an improved tolerability and safety proﬁle and is in line
with the FDA directive to use the lowest effective dose for the shortest
duration.
316
CLINICAL EVALUATION OF A HERBAL FORMULATION, RHULIEF™,
IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS
B. Antony1, R. Kizhakedath2, M. Benny1, B.T. Kuruvilla1. 1Arjuna Natural
Extracts Ltd., Aluva, India; 2Anugraha Med. Ctr., Kochi, India
Purpose: The study was conducted to evaluate the efﬁcacy, safety and
tolerability of Rhulief™, a unique mixture of acetyl boswellic acids
with acetyl 11-keto beta boswellic acid (AKBA) content of 10% w/w
and BCM 95®, a composition of curcumin which is about 7 times
more bioavailable than conventional curcumin, compared with non
steroidal anti-inﬂammatory drug, Celecoxib in the management of knee
Osteoarthritis.
Methods: Fifty four subjects were screened, 30 subjects were enrolled
and 28 completed the study. Subjects of both sexes aged 18 to
65 years who were medically stable with moderate form of osteoarthritis
evidenced by narrowing of the medial joint space with swelling were
randomized into two groups and were treated for a period of 12 weeks.
Gr I: Oral administration of Rhulief™ 500mg capsule twice daily
Gr II: Oral administration of Celecoxib 100mg capsule twice daily
Subjects with long standing and severe form of osteoarthritis, persons
with history of rheumatoid or reactive arthritis and signiﬁcant systemic
diseases were excluded from the study. Symptom scoring and clinical
examination were done during their each visit to ﬁnd out the efﬁcacy of
the drug. Safety of the drug was assessed by recording the liver function
test, renal function test and haemogram.
Results: The results of the symptom scoring revealed that there was a
signiﬁcant (p < 0.05) improvement in pain scores within the groups over a
period of 12 weeks and the improvement was more with Gr I. Signiﬁcant
(p < 0.05) improvement in walking distance and joint line tenderness
were also observed within the groups and the effects were greater with
Gr I. Statistically signiﬁcant difference between range of movements
were observed within both the groups (p < 0.05). The differences in
range of movements were comparable in both groups and there was
no signiﬁcant change between the two groups. Vital signs, haemogram,
liver function test and renal function test were not adversely modiﬁed by
Rhulief™. The results of the present study concluded that the treatment
was well-tolerated and did not produce any adverse effect in patients.
Conclusions: Rhulief™ at 500mg twice a day was better than Celecoxib
100mg twice daily in symptom scoring and clinical examination. It was
equally effective as Celecoxib in alleviating crepitus and range of joint
movements. The drug was well tolerated and no dose-related toxicity
was found. Efﬁcacy and tolerability of Rhulief™ used in the current
